CURIUM PHARMA UK LTD.
CURIUM PHARMA UK LTD.
CURIUM PHARMA UK LTD.
Company Registration Number:
09347432 (England and Wales)
Unaudited statutory accounts for the year ended 31 December 2020
Period of accounts
Start date: 1 January 2020
End date: 31 December 2020
CURIUM PHARMA UK LTD.
Contents of the Financial Statements
for the Period Ended 31 December 2020
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes |
CURIUM PHARMA UK LTD.
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 December 2020
Principal activities of the company
Directors
The directors shown below have held office during the whole of the period from
1 January 2020 to 31 December 2020
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
CURIUM PHARMA UK LTD.
Profit And Loss Account
for the Period Ended
2020 | 2019 | |
---|---|---|
| £ | £ |
Turnover: | | |
Cost of sales: | ( | ( |
Gross profit(or loss): | | |
Distribution costs: | | |
Administrative expenses: | ( | ( |
Other operating income: | | |
Operating profit(or loss): | | |
Interest receivable and similar income: | | |
Interest payable and similar charges: | ( | ( |
Profit(or loss) before tax: | | |
Tax: | ( | ( |
Profit(or loss) for the financial year: | | |
CURIUM PHARMA UK LTD.
Balance sheet
As at
Notes | 2020 | 2019 | |
---|---|---|---|
| £ | £ | |
Fixed assets | |||
Tangible assets: | 3 | | |
Total fixed assets: | | | |
Current assets | |||
Stocks: | 4 | | |
Debtors: | 5 | | |
Cash at bank and in hand: | | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 6 | ( | ( |
Net current assets (liabilities): | | | |
Total assets less current liabilities: | | | |
Accruals and deferred income: | ( | ( | |
Total net assets (liabilities): | | | |
Capital and reserves | |||
Called up share capital: | | | |
Profit and loss account: | | | |
Total Shareholders' funds: | | |
The notes form part of these financial statements
CURIUM PHARMA UK LTD.
Balance sheet statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
CURIUM PHARMA UK LTD.
Notes to the Financial Statements
for the Period Ended 31 December 2020
-
1. Accounting policies
Basis of measurement and preparation
These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102 Turnover policy
The company has suitable financial resources with a net asset position of £2,729,464. Credit risk is spread over numerous customers and the main customer is a public sector body. Order book levels remain constant and cash flow forecasting is undertaken weekly to ensure the business has enough cash resources to sustain it during the next year.Considering the above, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis in preparing the annual report and financial statements Tangible fixed assets depreciation policy
Tangible fixed assets are stated at cost.Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs and borrowing costs capitalized.Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives, and subject to impairment reviews, on the following bases:The estimated useful lives range as follows:Plant and machinery - 10 yearsComputer equipment - 3-5 yearsLeasehold improvements - 1-5 yearsThe assets' residual values and useful lives are reviewed, and adjusted, if appropriate, at the end of each reporting period. The effect of any change is accounted for prospectively. Valuation information and policy
At each balance sheet date non-financial assets not carried at fair value are assessed to determine whether there is an indication that the asset (or asset’s cash generating unit) may be impaired. If there is such an indication the recoverable amount of the asset (or asset’s cash generating unit) is compared to the carrying amount of the asset (or asset’s cash generating unit).The recoverable amount of the asset (or asset’s cash generating unit) is the higher of the fair value less costs to sell and value in use. Value in use is defined as the present value of the future cash flows before interest and tax obtainable as a result of the asset’s (or asset’s cash generating unit) continued use. These cash flows are discounted using a pre-tax discount rate that represents the current market risk-free rate and the risks inherent in the asset.If the recoverable amount of the asset (or asset’s cash generating unit) is estimated to be lower than the carrying amount, the carrying amount is reduced to its recoverable amount. An impairment loss is recognized in the profit and loss account, unless the asset has been revalued when the amount is recognized in other comprehensive income to the extent of any previously recognized revaluation. Thereafter any excess is recognized in the profit and loss account.If an impairment loss is subsequently reversed, the carrying amount of the asset (or asset’s cash generating unit) is increased to the revised estimate of its recoverable amount, but only to the extent that the revised carrying amount does not exceed the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized in prior periods. A reversal of an impairment loss is recognized in the profit and loss account.
CURIUM PHARMA UK LTD.
Notes to the Financial Statements
for the Period Ended 31 December 2020
-
2. Employees
2020 2019 Average number of employees during the period 50 34
CURIUM PHARMA UK LTD.
Notes to the Financial Statements
for the Period Ended 31 December 2020
3. Tangible assets
Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
---|---|---|---|---|---|---|
Cost | £ | £ | £ | £ | £ | £ |
At 1 January 2020 | | | | | ||
Additions | | | | | ||
Disposals | ||||||
Revaluations | ||||||
Transfers | ||||||
At 31 December 2020 | | | | | ||
Depreciation | ||||||
At 1 January 2020 | | | | | ||
Charge for year | | | | | ||
On disposals | ||||||
Other adjustments | ||||||
At 31 December 2020 | | | | | ||
Net book value | ||||||
At 31 December 2020 | | | | | ||
At 31 December 2019 | | | | |
CURIUM PHARMA UK LTD.
Notes to the Financial Statements
for the Period Ended 31 December 2020
4. Stocks
2020 | 2019 | |
---|---|---|
£ | £ | |
Stocks | | |
Total | | |
CURIUM PHARMA UK LTD.
Notes to the Financial Statements
for the Period Ended 31 December 2020
5. Debtors
2020 | 2019 | |
---|---|---|
£ | £ | |
Trade debtors | | |
Prepayments and accrued income | | |
Other debtors | | |
Total | | |
CURIUM PHARMA UK LTD.
Notes to the Financial Statements
for the Period Ended 31 December 2020
6. Creditors: amounts falling due within one year note
2020 | 2019 | |
---|---|---|
£ | £ | |
Trade creditors | | |
Taxation and social security | | |
Accruals and deferred income | | |
Other creditors | | |
Total | | |